Autoimmune diabetes can be transferred to young, diabetes prone BB/W rats by injecting them intravenously with conca-
Introduction
Spontaneous diabetes in the nonobese BB/W rat is similar to human Type I disease (1) . It develops in animals of both sexes between -60 and 120 d of age, and is characterized by the abrupt onset of severe hyperglycemia requiring insulin therapy. Many studies indicate an autoimmune etiology (2) (3) (4) (5) (6) ). An important characteristic finding is insulitis, suggesting cellmediated autoimmunity plays a role in the destruction of beta cells. This possibility is supported by the fact that antilymphocyte serum (7) , neonatal thymectomy (8) , and bone marrow transplantation (9) either reduce the incidence of or prevent diabetes.
Development of a means for passive transfer of diabetes using BB/W cells would provide an important model for investigating the pathogenesis of autoimmune diabetes. Furthermore, it would support the hypothesis that cell-mediated immunity plays a role in the pathogenesis of diabetes in these animals. In this regard, previous studies describe passive transfer of insulitis from acute diabetic BB rats to immunologically deficient athymic nude mice using spleen and peripheral blood cells (10) . However, these studies have proved difficult to repeat (1 1) . Passive transfer of insulitis from BB to X-irradiated BB recipients has also been briefly reported in a few animals (12) .
Interestingly, transfer of another autoimmune disease in rodents, experimental allergic encephalomyelitis, is significantly enhanced by culturing donor cells from affected animals with the T cell mitogen concanavalin A (Con A)' (13 of 12 d (14) .
In this study, we undertook to determine whether diabetes can be transferred to a normal strain of rat. This would provide data on whether beta cells from rats that do not normally develop diabetes can be recognized and selectively damaged by transfer of immune cells from an acute diabetic BB/W animal. Since the possibility exists that killing of beta cells through passive transfer involves donor immune cells restricted to the major histocompatibility complex (MHC) (i.e., they must first recognize self-MHC on the beta cells for killing to occur), we chose Wistar-Furth rats (MHC RTlU) as our recipients because they share MHC identity with BB rats (15) Recipient rats. 121 male and female Wistar-Furth rats (Sprague Dawley) between 3 and 4 mo of age served as recipients. Recipient animals were all immunosuppressed with cyclophosphamide (see below). They were divided into four groups receiving one of the following treatments: 1) Con A-stimulated spleen cells from acute diabetic BB/ W donor rats; 2) Con A-stimulated spleen cells from Wistar-Furth donor rats; 3) freshly isolated spleen cells (not Con A-stimulated) from acute diabetic BB/W donor rats; or 4) fresh RPMI medium alone.
Immunosuppression. Cyclophosphamide (Sigma Chemical Co., St. Louis, MO) was dissolved in sterile, isotonic saline. Recipient WistarFurth rats were injected intraperitoneally with doses of 100-150 mg/ kg body wt 1-2 d before the injection of cells. This dosage range was chosen because it is effective in suppressing cell-mediated immune processes (16) . Immunosuppressed rats were maintained on oxytetracycline (60 mg/dl, Terramycin; Pfizer Chemicals Div., Pfizer Inc., New York, NY) in hooded cages to reduce the likelihood of infection.
Glucose determinations and food consumption. Recipients from each of the four treatment groups were screened for glycosuria three times weekly. In addition, multiple determinations of plasma glucose concentrations were performed in animals from three of the treatment groups as follows: 1) recipients of Con A-stimulated BB/W cells had determinations twice a week, and then daily following a positive urine glucose test; 2) six recipients of Con A-stimulated Wistar-Furth cells had determinations twice a week, while remaining animals had a determination at the time of sacrifice 30 d after injection of cells; 3) recipients of freshly isolated BB/W cells had determinations twice a week for three weeks after injection of cells.
To provide a rough measure of health status, the amount of food consumed by immunosuppressed rats was measured and was compared with that of age-matched nonimmunosuppressed animals. This was done by weighing the food pellets daily in cages that housed four rats each. Three cages of animals were studied in each group.
Spleen cell culture. The cell culture procedure has been previously described (14) . Briefly, spleens from acute diabetic BB/W and control Wistar-Furth rats were removed aseptically and teased apart in RPMI 1640 medium (Gibco Laboratories, Grand Island, NY) containing 10% heat-inactivated fetal calf serum (HyClone Laboratories, Sterile Systems, Inc., Logan, UT), 5 mM glutamine, 5 X 10-1 M fl-mercaptoethanol, and 400 U/ml sodium penicillin. 100-300 X 106 cells were incubated in 150 ml RPMI 1640 containing 5 Studies of islet transplants to BB rats (9) are also relevant to this question. Recent results of Weringer and Like (19) show insulitis in isolated islets from various non-MHC compatible strains when these islets are transplanted under the renal capsule of diabetic BB/W rats. Since these animals retained a BB/W diabetic pancreas and had incompatible tissue grafts, it cannot be definitively concluded that the insulitis seen was associated with the beta cell cytotoxicity that leads to spontaneous diabetes. Preliminary results from our laboratory suggest an inability to transfer diabetes into the non-MHC compatible New England Deaconess Hospital strain (RTl1) (20) (n = 24).
Transfer studies using rats immunosuppressed with agents that obliterate all T cells could be useful in determining whether the immune cells responsible for beta cell destruction are present in the donor inoculum, or whether endogenous T cells need to be recruited. Similarly, studies of T cell lines developed from diabetic rats may be useful in this regard.
